Masimo Co. to Post FY2024 Earnings of $3.84 Per Share, Zacks Research Forecasts (NASDAQ:MASI)

Masimo Co. (NASDAQ:MASI) – Stock analysts at Zacks Research increased their FY2024 earnings per share estimates for Masimo in a research report issued on Thursday, September 26th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical equipment provider will post earnings per share of $3.84 for the year, up from their previous forecast of $3.81. The consensus estimate for Masimo’s current full-year earnings is $3.87 per share. Zacks Research also issued estimates for Masimo’s Q4 2024 earnings at $1.38 EPS, Q1 2025 earnings at $0.85 EPS, Q2 2025 earnings at $0.97 EPS, Q3 2025 earnings at $1.15 EPS, Q4 2025 earnings at $1.21 EPS, FY2025 earnings at $4.18 EPS, Q1 2026 earnings at $1.20 EPS, Q2 2026 earnings at $1.19 EPS and FY2026 earnings at $4.50 EPS.

Other equities research analysts have also recently issued research reports about the stock. Piper Sandler increased their target price on shares of Masimo from $160.00 to $165.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a report on Friday, September 20th. Four investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $144.67.

Masimo Trading Up 0.8 %

MASI stock opened at $134.40 on Monday. Masimo has a 1-year low of $75.22 and a 1-year high of $153.93. The company has a current ratio of 2.09, a quick ratio of 1.15 and a debt-to-equity ratio of 0.55. The business’s 50 day moving average is $117.71 and its 200-day moving average is $124.91. The firm has a market cap of $7.15 billion, a P/E ratio of 91.43 and a beta of 0.98.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $0.86 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.09. The company had revenue of $496.30 million during the quarter, compared to the consensus estimate of $493.92 million. Masimo had a net margin of 3.94% and a return on equity of 14.07%. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period last year, the firm earned $0.62 EPS.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Riverview Trust Co acquired a new position in shares of Masimo in the first quarter valued at $25,000. GAMMA Investing LLC increased its stake in Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after acquiring an additional 111 shares during the last quarter. Northwestern Mutual Wealth Management Co. lifted its position in shares of Masimo by 133.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 200 shares during the last quarter. Parallel Advisors LLC boosted its stake in Masimo by 48.3% in the fourth quarter. Parallel Advisors LLC now owns 445 shares of the medical equipment provider’s stock valued at $52,000 after buying an additional 145 shares in the last quarter. Finally, HHM Wealth Advisors LLC grew its position in Masimo by 25.0% in the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after acquiring an additional 125 shares during the last quarter. 85.96% of the stock is currently owned by institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.